We investigated the specific molecular mechanism in vivo and assessed the effect of this drug on the NF-κB/NLRP3 signalling pathway, to provide new insights for the intervention of SHYZD on AD from the perspective of inhibiting neuroinflammatory response. This evidence concerns the gene NFKB1 and Alzheimer disease.